Nevertheless, the authors emphasize that monitoring thyroid function in patients receiving GLP-1 analogs/receptor agonists is recommended, especially in the presence of other conditions that may increase the risk of CCH/thyroid cancer [77]. This evidence concerns the gene GCG and thyroid cancer.